SKLB610, identified by the CAS number 1125780-41-7, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in drug development. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds like SKLB610 are typically evaluated for their biological activity, pharmacokinetics, and toxicity profiles. It is often studied for its interactions with biological targets, which can include enzymes or receptors relevant to disease pathways. The compound may exhibit properties such as lipophilicity, which influences its absorption and distribution in biological systems. Additionally, its stability under various conditions is crucial for its efficacy as a therapeutic agent. As research progresses, detailed studies will provide more insights into its mechanism of action, potential therapeutic uses, and safety profile, making it a subject of interest in pharmaceutical research. For the most accurate and specific information, consulting scientific literature or databases is recommended.

SKLB610

1125780-41-7: SKLB610, identified by the CAS number 1125780-41-7, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in drug development. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds like SKLB610 are typically evaluated for their biological activity, pharmacokinetics, and toxicity profiles. It is often studied for its interactions with biological targets, which can include enzymes or receptors relevant to disease pathways. The compound may exhibit properties such as lipophilicity, which influences its absorption and distribution in biological systems. Additionally, its stability under various conditions is crucial for its efficacy as a therapeutic agent. As research progresses, detailed studies will provide more insights into its mechanism of action, potential therapeutic uses, and safety profile, making it a subject of interest in pharmaceutical research. For the most accurate and specific information, consulting scientific literature or databases is recommended.

SKLB 610

<p>SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively,</p>

CAS 1125780-41-7

SKLB610

SKLB 610

Ref: IN-DA008TJJ

SKLB 610

Ref: 54-BUP10703

SKLB 610

Ref: TM-T1895